Tamper Evidence in Pharma Packaging

We respect your privacy, by clicking "Download Your Copy" you will receive our e-newsletter, including information on Podcasts, Webinars, event discounts, online learning opportunities and agree to our User Agreement. You have the right to object . In addition, you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest subject to their privacy policy. For further information on how we process and monitor your personal data click here. You can unsubscribe at any time.

The anti-counterfeit packaging market is forecasted to reach US$206.57 billion by 2021, just shy of doubling its 2016 figure of $107.26 bn. This growth is supported by the expanding pharma and food and beverage industries, with Asia Pacific set to take the largest market share. China is earmarked to lead the way in 2021 with its drive in manufacturing activities fuelling that lead.

The anti-tampering market is littered with challenges to address: meeting EU FMD requirements, satisfying country specific requirements, preserving patient usability and not to mention outwitting resourceful counterfeiters. Ahead of the Packaging and Labelling Summit in June Pharma IQ explores the world of tamper evidence in pharma packaging

Insight from


Dieter Mößner

Convenor of ISO TC

Edelmann GmbH

122 WG 15 “Tamper Verification Features on medicinal product packaging

H 1

Horst Kastrup

Senior Regulatory Advisor

MEDA Pharma

Topics Discussed

• The road to meeting the 2019 FMD deadline

• Finding the most suitable antitamper evidence feature

• Efficient tamper evidence packaging that is also patient friendly

• Future trends

• About Packaging and Labelling 2017